The XPERT Study is testing whether a subcutaneous immunoglobulin (SCIG) can provide similar blood levels of immunoglobulin G (IgG) compared to an intravenous immunoglobulin (IVIG), in adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Researchers will also monitor safety and tolerability throughout the study and assess how often participants experience a worsening of their CIDP during treatment with SCIG compared to IVIG.
WHAT WILL HAPPEN?
Participation lasts approximately 40 weeks and includes:
- Screening: Up to 4 weeks
- IVIG Treatment Period: 19 weeks (7 intravenous infusions given every 3 weeks)
- Transition Period: 1 week
- SCIG Treatment Period: 16 weeks (weekly subcutaneous infusions)
WHO CAN JOIN?
You may be able to join if you:
- Are 18 years or older
- Have been diagnosed with CIDP
- Are being treated with intravenous immunoglobulins
WHAT TO EXPECT?
- Access to immunoglobulin therapy
- Local travel costs will be reimbursed
- Optional home health care service for particular visits
Learn More:
If youβd like more information, scan this QR code below, or contact us at clinicaltrials.gov/study/NCT07540221
Other Articles You May Like
New Research Offers Insight Into How Autoimmune Disorders May Develop
A newly published scientific paper explores how autoimmune disorders may arise, using Guillain-BarrΓ© syndrome (GBS)β¦
Shape The Future of CIDP Research
Study Title The Chronic Inflammatory Demyelinating Polyneuropathy-Health Index (CIDP-HI): Development of a Patient-Reported Outcome Measureβ¦
Advocating Locally with the Foundation
There's a persistent idea in advocacy that the work happens in Washington, that unless you'veβ¦